Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24869346 | 1.00 | SMARCA2 (0.49) | SMARCA2SMARCA4GRM4MALT1JAK2 | |
| SCHEMBL30875058 | 0.88 | SMARCA2 (0.44) | SMARCA2SMARCA4GRM4MALT1JAK2 | |
| SCHEMBL27216522 | 0.88 | SMARCA2 (0.44) | SMARCA2SMARCA4GRM4MALT1JAK2 | |
| SCHEMBL30875039 | 0.87 | GRM4 (0.47) | SMARCA2SMARCA4GRM4JAK2JAK1 | |
| SCHEMBL24869352 | 0.87 | GRM4 (0.47) | SMARCA2SMARCA4GRM4JAK2JAK1 | |
| SCHEMBL24869356 | 0.84 | SORT1 (0.42) | MALT1HDAC4HDAC6NPC1RAB9A | |
| SCHEMBL24869353 | 0.82 | PPARG (0.50) | GRM4MALT1PPARGALDH1A1HDAC4 | |
| SCHEMBL30875083 | 0.82 | PPARG (0.50) | GRM4MALT1PPARGALDH1A1HDAC4 | |
| SCHEMBL24869601 | 0.79 | SMARCA2 (0.43) | SMARCA2SMARCA4MALT1JAK2JAK1 | |
| SCHEMBL27216499 | 0.79 | MALT1 (0.51) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | MALT1, CYP51A1, BCR | SMARCA2 1782/4885SMARCA4 1849/4885GRM4 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.